New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2012
06:12 EDTEA, CVX, DE, AMX, RDS.A, BP, BRK.A, BA, XOM, AMOVOn the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: Gasoline prices dropped for the fifth consecutive week as the average price of regular gasoline fell to $3.790 a gallon yesterday, down 3.8% from the 2012 peak of $3.941 reached April 2, the Wall Street Journal reports...Electronic Arts (EA) will delay the release of an important, not yet identified game title past 2012, a significant factor dragging its sales expectations lower than analysts expected, the Wall Street Journal reports...U.S. airlines want the FAA to extend its deadline for modifying fuel tanks on hundreds of Boeing (BA) jets, the Wall Street Journal reports...REUTERS: America Movil (AMX, AMOV), the telecoms group controlled by Mexico's Carlos Slim, offered to buy a stake worth up to $4.2B in Dutch telecoms firm KPN (KKPNY) as a base for possible Europe expansion, Reuters reports...BLOOMBERG: Berkshire Hathaway's (BRK.A) Warren Buffett says his biggest acquisition is still to come, and that could attract the billionaire investor to companies from Deere & Co. (DE) to Henkel AG, Bloomberg reports.
News For A;DE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 21, 2015
15:27 EDTDEDeere May 88 weekly straddle priced for 3% movement into Q2
15:01 EDTDENotable companies reporting before tomorrow's open
Subscribe for More Information
08:11 EDTDEDeere May weekly volatility increases into Q2 and outlook
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
08:34 EDTDEDeere volatility elevated into Q2 and outlook
Subscribe for More Information
May 15, 2015
13:01 EDTDEOn The Fly: Top stock stories at midday
Subscribe for More Information
10:12 EDTDEJPMorgan says sell Deere ahead of potential liquidity crunch for farmers
Subscribe for More Information
10:01 EDTDEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:40 EDTDEEquity options with increasing volume
Subscribe for More Information
09:28 EDTDELongbow recommends avoiding Deere following global survey
Longbow's global agriculture survey shows that equipment demand has taken "another step down" in Q2 following a 27.1% decline in the Ag & Turf segment in Q1 amid commodity price weakness. The firm believes a recovery in commodity pricing is likely to be pushed out "several" planting cycles. It keeps its below consensus estimates for Deere and recommends not holding the stock. Longbow has an Underperform rating on the name with a $72 price target. Deere was downgraded this morning at JPMorgan to Underweight.
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
06:43 EDTDEDeere downgraded to Underweight from Neutral at JPMorgan
Subscribe for More Information
May 13, 2015
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
May 12, 2015
14:48 EDTDEWASDE report bearish for ag equipment demand, says Wells Fargo
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use